Last reviewed · How we verify
GSK Biologicals' acellular pertussis vaccine
GSK Biologicals' acellular pertussis vaccine is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development.
At a glance
| Generic name | GSK Biologicals' acellular pertussis vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 3 |
Approved indications
Common side effects
- Pain
- Pyrexia
- Irritability
- Nasopharyngitis
- Somnolence
- Swelling
- Erythema
- Diarrhoea
- Decreased appetite
- Anaemia
- Gastroenteritis
- Bronchiolitis
Key clinical trials
- Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea
- Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines (PHASE3)
- This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine (PHASE3)
- Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) (PHASE2)
- Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old (PHASE3)
- Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines (PHASE3)
- Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose (PHASE2)
- Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK Biologicals' acellular pertussis vaccine CI brief — competitive landscape report
- GSK Biologicals' acellular pertussis vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK Biologicals' acellular pertussis vaccine
What is GSK Biologicals' acellular pertussis vaccine?
GSK Biologicals' acellular pertussis vaccine is a Biologic drug developed by GlaxoSmithKline.
Who makes GSK Biologicals' acellular pertussis vaccine?
GSK Biologicals' acellular pertussis vaccine is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is GSK Biologicals' acellular pertussis vaccine in?
GSK Biologicals' acellular pertussis vaccine is in Phase 3.
What are the side effects of GSK Biologicals' acellular pertussis vaccine?
Common side effects of GSK Biologicals' acellular pertussis vaccine include Pain, Pyrexia, Irritability, Nasopharyngitis, Somnolence, Swelling.